Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
PLYX
Strong SellSinkerPolaryx Therapeutics, Inc. · Healthcare · United States · $103M · Avg Vol: $191K/d
5
StockRankGet insider-trade alerts
Q
31
V
23
M
18
P/E (TTM)
—
ROE
-96.6%
D/E
0.0x
Dividend %
—
COMPANY DESCRIPTION
Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States.
FINANCIAL SUMMARY (USD)
| Year | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | — | — | — | — | — |
| EPS | -0.08 | -0.64 | -0.19 | — | -0.14 | -0.20 | -0.29 | — |
| Shares | 47.3M | 47.3M | 47.3M | 0.0% | 49.8M | — | — | — |
| Debt | 0.1M | — | — | — | — | — | — | — |
| Equity | 1.3M | 4.7M | 4.6M | 89.1% | — | — | — | — |
| Op CF | -0.2M | -2.6M | -3.9M | — | -5.8M | — | — | — |
| Inv CF | — | — | — | — | — | — | — | — |
| Fin CF | 0.1M | 7.2M | 4.5M | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)-7.4%
SMA 50SMA 200
Close
$1.99
RSI (14)
41.9
SCORE BREAKDOWN
Quality
31
ROIC
-103.5%6.3
ROE
-96.6%9.9
GP/Assets
—N/A
Op. Margin
0.0%38.1
FCF/Assets
-29.6%13.9
Piotroski
324.5
Int. Cover
—N/A
D/E Ratio
0.00x98.1
Current Ratio
13.53x91.7
Value
23
P/E (TTM)
—N/A
EV/EBITDA
—N/A
P/FCF
—N/A
P/B
9.1x13.2
P/S
—N/A
Div Yield
—N/A
Momentum
18
52W High %
—N/A
RS 6M
-78%3.3
SMA 50/200
—N/A
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$103M
P/E (Forward)
—
Gross Margin
—
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PLYX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| PLYX | Polaryx Therapeutics, Inc.(you) | $103M | 5 | Strong Sell |
| ONCY | Oncolytics Biotech Inc. | $109M | 5 | Strong Sell |
| NAUT | Nautilus Biotechnology, Inc. | $113M | 4 | Strong Sell |
| ALDX | Aldeyra Therapeutics, Inc. | $90M | 4 | Strong Sell |
| GNLX | Genelux Corporation | $120M | 4 | Strong Sell |
| VRCA | Verrica Pharmaceuticals Inc. | $98M | 7 | Strong Sell |
| KLRS | Kalaris Therapeutics, Inc. | $96M | 7 | Strong Sell |
| RANI | Rani Therapeutics Holdings, Inc. | $118M | 7 | Strong Sell |
| COYA | Coya Therapeutics, Inc. | $108M | 10 | Strong Sell |
| CBUS | Cibus, Inc. | $126M | 2 | Strong Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.3%